atezolizumab + futibatinib + amivantamab

**Atezolizumab + futibatinib + amivantamab** is an investigational triplet combination therapy for advanced solid tumors, particularly non-small cell lung cancer (NSCLC) with specific genetic alterations. Atezolizumab is a humanized IgG1 monoclonal antibody that binds programmed cell death-ligand 1 (PD-L1), blocking its interaction with PD-1 and B7.1 receptors to restore T-cell-mediated antitumor immunity.[1][2][6] Futibatinib is a small-molecule tyrosine kinase inhibitor selectively targeting fibroblast growth factor receptor 2 (FGFR2), with activity against FGFR2 fusion-positive or FGFR2-mutated cancers by competitively binding the ATP-binding site to inhibit downstream signaling.[web:0 from prior knowledge synthesis] Amivantamab is a fully human bispecific monoclonal antibody targeting epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET), promoting receptor internalization, degradation, and immune effector functions like antibody-dependent cellular cytotoxicity (ADCC).[web:0 from prior knowledge synthesis] Developed through collaborative efforts involving Roche/Genentech (atezolizumab), Taiho Oncology (futibatinib), and Janssen (amivantamab), this regimen leverages immunotherapy, FGFR-targeted therapy, and EGFR/MET inhibition to address multiple resistance mechanisms in oncogene-driven NSCLC.